Current Application of Continuous Glucose Monitoring in the Treatment of Diabetes
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The ultimate goal of diabetes technology is to create an artificial pancreas, or closed-loop system. In the early 1970s, the first prototypes became available (1). Although recent advances are promising, the closed-loop system is currently confined to the clinical research center (2). The continuous subcutaneous insulin infusion (CSII) pump became commercially available in the 1980s, and it is now a common and accepted way of providing insulin (3,4). The emergence of continuous glucose monitoring (CGM) followed in the 1990s, with the first reports on CGM by microdialysis in 1992 (5,6). Retrospective needle-type CGM systems were introduced just before the turn of the century (7–10). Currently, there are four subcutaneous CGM systems on the market that have real-time glucose values on display every 1–5 min and feature an alarm function for hypo- and hyperglycemia: the Freestyle Navigator (Abbot Diabetes Care, Alameda, CA), the Guardian Real-Time (Medtronic MiniMed, Northridge, CA), the Dexcom SEVEN (Dexcom, San Diego, CA), and the GlucoDay (Menarini Diagnostics). The first three are needle-type CGMs and the latter is a microdialysis-type sensor. All of these measure glucose via the glucose-oxidase reaction. In this article, we will discuss the pros and cons of the current application of CGM in the treatment of diabetes. From the Diabetes Control and Complications Trial and the UK Prospective Diabetes Study, we learned that lowering HbA1c reduces morbidity and mortality (11,12) and that tight glycemic control is associated with an increased rate of severe hypoglycemic episodes. We therefore should judge the pros of CGM by its HbA1c-lowering potency and its influence on severe hypoglycemia rates. Table 1 summarizes all intervention trials that have been performed with real-time CGM regarding HbA1c and the incidence of severe hypoglycemia. View this table: Table 1 CGM trials in type 1 diabetes The …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Assessment of Diabetes-Related Distress
Polonsky, W. H., Anderson, B. J., Lohrer, P. A., Welch, G., Jacobson, A. M., Aponte, J. E., & Schwartz, C. E. (1995) · Diabetes Care · doi:10.2337/diacare.18.6.754 · Cited by 1,497 · cited 1×
“In the Eurythmics trial, patients randomized to CGM-augmented CSII experienced significantly less problems with their diabetes and increased treatment satisfaction as measured by the Problem Area In Diabetes questionnaire and the Diabetes Treatment Satisfaction questionnaire (20,23,24).”
MethodCryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160 · cited 1×
“Second, during severe hypoglycemia, there is a decline of cognitive function and patients are less adequate in responding to acoustic or vibration alarms (38).”
BackgroundEffectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894 · cited 1×
“HbA1c decreased after 1 year in the CSII augmented with CGM group compared with continuation of injection treatment and SMBG in both children and adults (Table 1) (21).”
MethodDeiss, D., Bolinder, J., Riveline, J.-P., Battelino, T., Bosi, E., Tubiana-Rufi, N., Kerr, D., & Phillip, M. (2006) · Diabetes Care · doi:10.2337/dc06-1134 · Cited by 539
Self-citationThe effect of continuous glucose monitoring in well-controlled type 1 diabetes
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0108 · Cited by 399
Murphy, H. R., Rayman, G., Lewis, K., Kelly, S., Johal, B., Duffield, K., Fowler, D., Campbell, P. J., & Temple, R. C. (2008) · BMJ · doi:10.1136/bmj.a1680 · Cited by 358 · cited 1×
“In an Australian RCT, 71 women with type 1 diabetes were randomized to antenatal care with CGM at 4- to- 6-week intervals during pregnancy or to standard antenatal care (27).”
Effectiveness of Continuous Glucose Monitoring in a Clinical Care Environment
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2010) · Diabetes Care · doi:10.2337/dc09-1502 · Cited by 313
Yoo, H. J., An, H. G., Park, S. Y., Ryu, O. H., Kim, H. Y., Seo, J. A., Hong, E. G., Shin, D. H., Kim, Y. H., Kim, S. G., et al. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.06.015 · Cited by 244 · cited 1×
“(40) performed an RCT in 65 patients with type 2 diabetes, comparing 12 weeks of intermittent real-time CGM use (3 days per month) with standard care using SMBG.”
MethodBode, B. W., Gross, T. M., Thornton, K. R., & Mastrototaro, J. J. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00113-8 · Cited by 232
Clarke, W. L., Anderson, S., Breton, M., Patek, S., Kashmer, L., & Kovatchev, B. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300506 · Cited by 185
Cited by
Tanenbaum, M. L., Hanes, S. J., Miller, K. M., Naranjo, D., Bensen, R., & Hood, K. K. (2017) · Diabetes Care · doi:10.2337/dc16-1536 · Cited by 296
Clinical accuracy of a continuous glucose monitoring system with an advanced algorithm
Bailey, T. S., Chang, A., & Christiansen, M. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814559746 · Cited by 168
Optimal use of diabetes devices: clinician perspectives on barriers and adherence to device use
Tanenbaum, M. L., Adams, R. N., Hanes, S. J., Barley, R. C., Miller, K. M., Mulvaney, S. A., & Hood, K. K. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816688010 · Cited by 117
Barriers to continuous glucose monitoring in people with type 1 diabetes: clinician perspectives
Lanning, M. S., Tanenbaum, M. L., Wong, J. J., & Hood, K. K. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0039 · Cited by 40
Soare, A., Khazrai, Y. M., Fontana, L., Del Toro, R., Lazzaro, M. C., Di Rosa, C., Buldo, A., Fioriti, E., Maddaloni, E., Angeletti, S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.01.023 · Cited by 15
Metadata
- Authors
- Hermanides, J., Phillip, M., & DeVries, J. H.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-04-22
- Volume
- 34
- Issue
- Supplement_2
- Pages
- S197-S201
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2065937263
- Cited by
- 57
- References
- 11
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.